Immunic, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-97.2M | $-100.5M | $-93.6M | $-120.4M | $-92.9M | $-44.0M | $-34.9M | $-11.5M |
| Depreciation & Amortization | $168.0K | $134.0K | $111.0K | $77.0K | $85.0K | $39.0K | $50.0K | $15.0K |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $8.9M | $8.5M | $7.1M | $7.9M | $5.9M | $2.7M | $6.5M | $0 |
| Net Cash from Operating Activities | $-85.8M | $-84.8M | $-70.8M | $-65.1M | $-83.2M | $-46.1M | $-28.5M | $-9.7M |
| Investing Activities | ||||||||
| Capital Expenditures | $161.0K | $264.0K | $334.0K | $112.0K | $67.0K | $146.0K | $55.0K | $32.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-161.0K | $-264.0K | $9.5M | $-9.7M | $-67.0K | $-146.0K | $10.5M | $-32.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $65.6M | $74.5M | $1.0M | $95.8M | $42.8M | $144.4M | $34.9M | $19.3M |
| Net Change in Cash | $-20.2M | $-11.0M | $-60.1M | $19.9M | $-40.6M | $98.1M | $16.3M | $-43.6M |
| Free Cash Flow | $-86.0M | $-85.0M | $-71.2M | $-65.3M | $-83.3M | $-46.3M | $-28.6M | $-9.8M |